Welcome to LookChem.com Sign In|Join Free
  • or
17-benzimidazol-1-yl-androsta-3,5,16-triene is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

908581-05-5

Post Buying Request

908581-05-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

908581-05-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 908581-05-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,8,5,8 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 908581-05:
(8*9)+(7*0)+(6*8)+(5*5)+(4*8)+(3*1)+(2*0)+(1*5)=185
185 % 10 = 5
So 908581-05-5 is a valid CAS Registry Number.

908581-05-5Upstream product

908581-05-5Downstream Products

908581-05-5Relevant academic research and scientific papers

Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate

Purushottamachar, Puranik,Kwegyir-Afful, Andrew K.,Martin, Marlena S.,Ramamurthy, Vidya P.,Ramalingam, Senthilmurugan,Njar, Vincent C. O.

, p. 708 - 713 (2016)

Degradation of all forms of androgen receptors (ARs) is emerging as an advantageous therapeutic paradigm for the effective treatment of prostate cancer. In continuation of our program to identify and develop improved efficacious novel small-molecule agents designed to disrupt AR signaling through enhanced AR degradation, we have designed, synthesized, and evaluated novel C-3 modified analogues of our phase 3 clinical agent, galeterone (5). Concerns of potential in vivo stability of our recently discovered more efficacious galeterone 3β-imidazole carbamate (6) led to the design and synthesis of new steroidal compounds. Two of the 11 compounds, 3β-pyridyl ether (8) and 3β-imidazole (17) with antiproliferative GI50 values of 3.24 and 2.54 μM against CWR22Rv1 prostate cancer cell, are 2.75- and 3.5-fold superior to 5. In addition, compounds 8 and 17 possess improved (~4-fold) AR-V7 degrading activities. Importantly, these two compounds are expected to be metabolically stable, making them suitable for further development as new therapeutics against all forms of prostate cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 908581-05-5